A large study has found an intriguing link between estrogen hormone therapy and brain health in older women.
Women who had used the treatment later in life were less likely to be diagnosed with dementia and also showed fewer signs of Alzheimer’s disease in their brains.
The findings were published August 12, 2026, in Neurology, the medical journal of the American Academy of Neurology. Researchers stressed that the study found an association and does not prove that estrogen therapy prevents Alzheimer’s disease or other forms of dementia.
The study was led by Jennifer Bruno of Stanford Medicine. Bruno said the findings may help scientists understand the relationship between hormones and the aging brain, but they are not enough to recommend hormone therapy as a way to protect memory.
Hormone therapy is commonly used to relieve symptoms related to menopause, including hot flashes and night sweats. Estrogen levels fall during menopause, and replacing some of this hormone can improve symptoms for certain women.
However, hormone therapy is not one single treatment. Different medicines can contain estrogen alone or estrogen combined with a form of progesterone, and the health effects can depend on the type of treatment, a woman’s age, when treatment begins, and her medical history.
The new analysis focused only on estrogen-only therapy. Today, estrogen without progestogen is generally used systemically in women who have had their uterus removed because estrogen alone can increase the risk of cancer of the uterine lining in women who still have a uterus.
Researchers examined information from two large data sets containing 21,462 women who had undergone medical and cognitive testing while alive. Their average age when follow-up began was about 71, and they were followed for roughly three to five years.
Of the entire group, 1,953 women had used hormone therapy and 19,509 had not. The women who received hormone therapy had begun it at an average age above 70, making their treatment pattern quite different from the way menopausal hormone therapy is usually prescribed today.
One part of the study included 2,959 women whose brains were examined after death. Their average age at autopsy was 82, allowing researchers to look directly for physical changes associated with Alzheimer’s disease.
Alzheimer’s disease involves several abnormal changes in the brain. Two of the best known are deposits of amyloid-beta protein, called plaques, and abnormal tau protein that forms tangles inside nerve cells.
The researchers also examined neuritic plaques, which are amyloid deposits surrounded by damaged nerve fibers. They combined information about these three features to estimate the overall amount of Alzheimer’s-related disease in each brain.
Among women who had used estrogen therapy, 18% had none of the three Alzheimer’s signs at autopsy. Only 10% of women who had not used hormone therapy showed no signs.
The pattern was also different among women with the greatest amount of Alzheimer’s-related damage. About 40% of hormone therapy users showed all three signs, compared with 51% of women who had not used the treatment.
Researchers then adjusted their calculations for factors that could influence dementia risk, including age, education, race, high blood pressure, and genetic differences. After these adjustments, hormone therapy use was associated with 35% lower odds of showing Alzheimer’s-related changes at autopsy.
A smaller group of 728 participants underwent brain scans or tests of biological markers while they were alive. These tests provided another way to look for changes connected with Alzheimer’s disease without relying only on memory testing.
The results suggested less amyloid buildup among women who had used hormone therapy. Their blood and spinal-fluid measurements showed a pattern consistent with less amyloid being deposited as plaques in the brain.
The clinical findings pointed in a similar direction. Women who had used estrogen therapy had 39% lower odds of receiving a dementia diagnosis and were less likely to have memory difficulties or problems performing everyday activities.
These results may sound promising, but they need careful interpretation. The study looked backward at women who had already chosen or been prescribed hormone therapy, rather than randomly assigning women to receive estrogen or no treatment.
This means the two groups may have differed in important ways that researchers could not fully measure. Women who received hormone therapy, for example, might have differed in their overall health, access to healthcare, socioeconomic circumstances, or other factors that could influence dementia risk.
Timing is another major issue. The women in this study generally used estrogen much later in life than women beginning menopausal hormone therapy under current medical practice, which often starts around the menopausal transition rather than after age 70.
Earlier research on hormones and dementia has produced complicated and sometimes conflicting results. Some studies have suggested that the type of hormone treatment and the age at which it begins may substantially change its effects on the brain.
For that reason, this study should not be read as evidence that older women should begin estrogen to prevent dementia. Hormone therapy has benefits and risks that vary from person to person, and decisions about its use should be based on established medical reasons and an individual’s health profile.
The study’s strength is that several different measures pointed in the same direction, including clinical dementia diagnoses, memory and daily functioning, biological markers, and findings from brain autopsies. That consistency makes the association scientifically interesting and worth investigating further.
Still, association is not causation, and the unusual age and treatment patterns of these participants limit how directly the findings apply to women today. Randomized or carefully designed prospective studies would be needed to determine whether estrogen itself produces the apparent brain benefits and whether timing changes the effect.
Overall, the research adds an important piece to the complicated story of hormones and brain aging. It raises the possibility that estrogen exposure may be connected with Alzheimer’s-related processes, but it does not establish hormone therapy as a dementia prevention treatment.
Source: Stanford Medicine
